Investor service announcement no. 1/2012


To: NASDAQ OMX Copenhagen
Hørsholm, Denmark, March
1, 2012


Veloxis Pharmaceuticals A/S to Host Conference Call to Announcing Annual Report
2011



Veloxis Pharmaceuticals A/S (OMX: VELO) will announce the Annual Report 2011 on
Wednesday March 7, 2012 after 1 pm CET. Veloxis’ Management will host a
conference call on March 7, 2012, at 2:00 PM CET (Denmark); 1:00 PM GMT
(London), 08:00 AM ET (New York), 5:00 AM PT (San Francisco) to discuss the
financial results.


To access the live conference call, please dial one of the following numbers:

+45 32 72 76 25 Denmark

+44 (0) 1452 555 566 UK

+1 631 510 7498 USA

Access code 57134951


Following the conference call, an audiocast will be available on the company’s
website www.veloxis.com. A presentation will be available on Veloxis’ website
(under ‘Investors’) one hour prior to the scheduled time of the conference
call.


For more information, please contact:


John Weinberg, M.D. Johnny Stilou
SVP, Commercial Operations & Investor Relations Chief Financial Officer
Tlf: +1 908 304 3389 Tlf: +45 21 227 227
Email: [email protected] Email: [email protected]


Veloxis Pharmaceuticals A/S (VELO)

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis
Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company.
Clinical development is the core of Veloxis’ efforts to develop a product
portfolio which includes the Company’s lead product candidate, LCP‐Tacro™, for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. Veloxis adapts new technologies on a fast
commercial timetable. Veloxis’ unique, patented delivery technology, MeltDose®,
can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only
for a broad spectrum of drugs already on the market but also for new chemical
entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the
U.S. market and a diversified near and medium term pipeline with three clinical
stage product candidates and a number of projects in preclinical development.
Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX:
VELO.

For further information, please visit www.veloxis.com.

070312 Veloxis Pharmaceuticals to Host Annual Report 2011 call.pdf